Trubion Pharmaceuticals Inc. (TRBN)

[surf1944]

8:25AM Trubion Pharma reports "positive data" from Phase 2b Re-treatment study of TRU-015 (TRBN) 4.65 : Co announces favorable safety and efficacy data following administration of a second course of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis. These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b RA study of TRU-015. Pfizer (PFE) and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including R.A. Data from the open-label re-treatment phase of the Phase 2b study demonstrate that repeat administration with TRU-015 is generally well-tolerated and results in sustained improvement in the signs and symptoms of RA. The Phase 2b trial is a double-blind, placebo-controlled, randomized study that is designed to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of repeat doses of TRU-015. Of the 276 original patients who began the study, 240 (204 of whom were rheumatoid-factor positive, or RF+) entered the first open-label re-treatment portion of the trial. Of the 276 original patients who began the study, 240 (204 of whom were rheumatoid-factor positive, or RF+) entered the first open-label re-treatment portion of the trial.